Calcimedicaincis A Clinical Stage Biopharmaceutical Company Dedicated To Developing Innovative Therapies For Life Threatening Inflammatory Diseasesthe Company Focuses On Calcium Release Activated Calciumcracchannel Inhibitionleveraging Its Proprietary Platform To Address Significant Unmet Medical Needs In Acute Inflammatory Conditions One Of Calcimedica S Key Product Candidates Is Auxoraa Czegocractin An Intravenous Small Molecule Crac Channel Inhibitorit Is Being Investigated For Various Indicationsincluding Acute Pancreatitisacute Kidney Injuryand Acute Respiratory Distress Syndromethe Company Is Currently Advancing Auxoraa C Through Phase 2B Trialswith Results Expected In Late 2023 Calcimedica Operates As A Publicly Traded Entity On Nasdaq Under The Tickercalcfollowing Its Merger With Graybug Vision In 2023The Company Has Secured Funding To Support Its Operations And Is Focused On Expanding Its Clinical Pipeline While Collaborating With Academic And Pharmaceutical Partners To Enhance Drug Development
